
Pharma major Eisai (TYO: 4523) on Tuesday said the Japanese regulators have stalled the approval of its drug to treat …

Eisai is hoping that existing neurology drug mecobalamin can be a new option for the difficult-to-treat condition amyotrophic lateral sclerosis …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales

